Where Beam Therapeutics Stands With Analysts
Within the last quarter, Beam Therapeutics (NASDAQ:BEAM) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…
Beam Therapeutics Expects Cash, Cash Equivalents, And Marketable Securities Of $1.1B Will Enable The Company To Fund Its Anticipated Operating Expenses And Capital Expenditure Requirements At Least Into 2025
This expectation includes funding directed toward reaching each of the key milestones for BEAM-101, BEAM-201, BEAM-301 and BEAM-302 described above, as well as continued investments in platform advancements and
Beam Therapeutics Q4 EPS $(0.54) Beats $(1.33) Estimate, Sales $20.04M Beat $12.53M Estimate
Beam Therapeutics (NASDAQ:BEAM) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(1.33) by 59.4 percent. This is a 43.16 percent increase over losses of $(0.95) per share from
Analyst Ratings for Beam Therapeutics
Within the last quarter, Beam Therapeutics (NASDAQ:BEAM) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…
Cantor Fitzgerald Initiates Coverage On Beam Therapeutics with Overweight Rating, Announces Price Target of $62
Cantor Fitzgerald analyst Rick Bienkowski initiates coverage on Beam Therapeutics (NASDAQ:BEAM) with a Overweight rating and announces Price Target of $62.
Beam Therapeutics Reports Progress Across Base Editing Portfolio And Outlines Key Anticipated Milestones
BEACON Trial of BEAM-101 in Sickle Cell Disease Ongoing with Data from Multiple Patients Expected in 2024; Expansion Phase Initiation Expected in 2023
First Patient Dosing in BEAM-201 Trial in Patients with
Cathie Wood Gets Elon Musk’s Attention Over Gene-Editing Therapy Potential: ‘Investors Chased The Dream Then. Now, They’re Running Away’
Cathie Wood of ARK Investment Management believes U.S. equity markets are the polar opposite of what they were in the 90s when investors chased their dreams.
4 Analysts Have This to Say About Beam Therapeutics
Analysts have provided the following ratings for Beam Therapeutics (NASDAQ:BEAM) within the last quarter: Bullish Somewhat Bullish Indifferent…
Analyst Beefs Up Beam Therapeutics Price Target, Says ‘Reward Is Now Skewed To Upside’
BMO Capital Markets has upgraded Beam Therapeutics Inc (NASDAQ:BEAM) from Market Perform to Outperform and raised the price target from $61 to…
Tesla To $285? Here Are 10 Other Price Target Changes For Tuesday
Wells Fargo raised Ross Stores, Inc. (NASDAQ: ROST) price target from $120 to $135. Wells Fargo analyst Ike Boruchow maintained an Overweight rating on the stock. Ross Stores shares fell 0.9% to close at $114.92 on Friday.